| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
| Targets |
The specific molecular targets of 4-(Methylhydroxyphosphinyl)-2-oxobutyric acid are not well characterized in the available literature. The compound contains a phosphinic acid group, which is a structural feature found in various enzyme inhibitors, particularly those targeting metalloproteases and other enzymes that utilize phosphoryl transfer reactions. The compound may serve as a chemical intermediate or building block for the synthesis of bioactive compounds.
|
|---|---|
| ln Vitro |
Specific in vitro activity data for 4-(Methylhydroxyphosphinyl)-2-oxobutyric acid are not reported in the available literature. The compound is primarily used as a chemical intermediate or research reagent rather than as a pharmacologically active agent. Its biological activity, if any, would depend on the specific context of use. The compound is classified under "Others" in chemical databases, indicating limited characterization of its biological properties.
|
| ln Vivo |
Specific in vivo data for 4-(Methylhydroxyphosphinyl)-2-oxobutyric acid are not reported. The compound is not described as a therapeutic agent but rather as a chemical building block or research reagent. No in vivo studies have been reported in the available literature.
|
| Enzyme Assay |
The characterization of 4-(Methylhydroxyphosphinyl)-2-oxobutyric acid is performed using standard analytical chemistry methods. The compound is analyzed by HPLC for purity (typically ≥98%) and by mass spectrometry for molecular weight confirmation. NMR spectroscopy may be used for structural confirmation. No specific biological assay protocols are reported for this compound.
|
| Cell Assay |
No specific cellular assay protocols for 4-(Methylhydroxyphosphinyl)-2-oxobutyric acid are reported in the available literature. The compound is not typically used in cell-based assays as it is a chemical intermediate rather than a biologically active compound. If used in research, standard cell culture protocols would apply depending on the specific application. The compound has a molecular weight of 180.1 g/mol.
|
| Animal Protocol |
No specific in vivo animal protocols for 4-(Methylhydroxyphosphinyl)-2-oxobutyric acid are reported in the available literature. The compound is not a therapeutic agent and is not typically used in animal studies.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for 4-(Methylhydroxyphosphinyl)-2-oxobutyric acid are not reported. The compound has a molecular weight of 180.1 g/mol and a molecular formula of C₅H₉O₅P. Its small size and polar nature suggest it may have reasonable water solubility. The compound is typically stored at room temperature or as specified by the manufacturer.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for 4-(Methylhydroxyphosphinyl)-2-oxobutyric acid are not reported. As a chemical intermediate, comprehensive toxicology studies have not been performed. The compound should be handled with appropriate safety precautions in laboratory settings, including the use of gloves, eye protection, and proper ventilation. Material safety data sheets should be consulted for detailed safety information.
|
| Additional Infomation |
4-(Methylhydroxyphosphinyl)-2-oxobutyric acid is a chemical compound with the molecular formula C₅H₉O₅P and a molecular weight of 180.1 g/mol. It is used in pharmaceutical research and development. No biological activity or clinical applications have been reported. For research use only.
|
| Molecular Formula |
C5H9O5P
|
|---|---|
| Molecular Weight |
180.1
|
| Exact Mass |
179.011
|
| CAS # |
79778-02-2
|
| PubChem CID |
22328393
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
11
|
| Complexity |
187
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OCP(CCC(=O)C(O)=O)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 2 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.5525 mL | 27.7624 mL | 55.5247 mL | |
| 5 mM | 1.1105 mL | 5.5525 mL | 11.1049 mL | |
| 10 mM | 0.5552 mL | 2.7762 mL | 5.5525 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
